Mutations in both BRCA1 and BRCA2 are characterised by predisposition to breast cancer and ovarian cancer as well as prostate cancer (BRCA1) and other cancers (BRCA2).

The risk of developing cancer that is associated with BRCA1 and BRCA2 cancer-predisposing mutations is not known and appears to be variable even within families of similar ethnic background with the same mutation.

Estimates of breast cancer and ovarian cancer risks have been derived from families with multiple affected individuals as well as from families with few affected individuals and from population-based studies.

Prognosis for breast cancer survival depends upon the stage at which breast cancer is diagnosed and may not be different between individuals with BRCA1 or BRCA2 cancer-predisposing mutations and controls.

Cancer-predisposing mutations in the BRCA1 and BRCA2 genes are inherited in an autosomal dominant manner. It is preferable to identify the specific cancer-predisposing mutation in an affected family member first; then, molecular genetic testing of either the BRCA1 or BRCA2 gene can be used in genetic counselling and testing of asymptomatic at-risk family members. Offspring of individuals with a BRCA1 or BRCA2 cancer-predisposing mutation have a 50% chance of inheriting the gene mutation. Prenatal testing is possible for foetuses at 50% risk; however, requests for prenatal diagnosis of adult-onset diseases are uncommon and require careful genetic counselling.

click to expand section

Blood Sample Kit
click to expand section

Postage & Packaging
click to expand section

Laboratory Analysis
click to expand section

Medical Questionnaire
click to expand section

Interpretation of Results
click to expand section

Copy of Laboratory Results
click to expand section

Helpline Card
click to expand section

Contact MediChecks prior to purchase. Doctor/Consultant referral OLNY.
Blood test

45   working days after receipt of sample.


(All mutations)